Optimal effect-site concentration of remifentanil for preventing cough during removal of the double-lumen endotracheal tube from sevoflurane-remifentanil anesthesia

A prospective clinical trial

Sook Young Lee (MD, PhD)a, Ji Young Yoo (MD, PhD)a, Jong Yeop Kim (MD, PhD)a, Dae Hee Kim (MD)a, Jung Dong Lee (MS)b, Go Un Rho (MD)a, Hyungbae Park (MD)a, Sung Yong Park (MD)a,∗

Abstract

Opioids are used as a treatment for coughing. Recent studies have reported an antitussive effect of remifentanil during recovery from general anesthesia by suppressed coughing. The coughing reflex may differ throughout the respiratory tract from the larynx to the bronchi. But the proper dose of remifentanil to prevent cough during double-lumen tube (DLT) extubation is unknown.

Twenty-five ASA physical status 1 and 2 patients, 20 to 65 years of age who were undergoing video-assisted thoracoscopic lung surgery requiring 1-lung ventilation were enrolled. The effective effect-site concentration (Ce) of remifentanil for 50% and 95% of patients (EC50 and EC95) for preventing cough was determined using the isotonic regression method with a bootstrapping approach, following the Dixon up-and-down method. Recovery profiles and hemodynamic values after anesthesia were compared between patients with cough and patients without cough.

EC50 and EC95 of remifentanil was 1.670ng/mL [95% confidence interval (95% CI) 1.393–1.806] and 2.275ng/mL (95% CI 1.950–2.263), respectively. There were no differences in recovery profiles and hemodynamic values after anesthesia between patients with/without cough. No patients suffered respiratory complications during the emergence period.

Remifentanil can be a safe and reliable method of cough prevention during emergence from sevoflurane anesthesia after thoracic surgery requiring DLT. EC50 and EC95 of remifentanil that suppresses coughing is 1.670 and 2.275ng/mL, respectively.

Abbreviations: ASA = American Society of Anesthesiologists, BIS = bispectral index, Ce = effect-site concentration, CI = confidence interval, DLT = double-lumen tube, EC50 = effective effect-site concentration for 50%, EC95 = effective effect-site concentration for 95%, PAVA = pooled adjacent violators algorithm, SLT = single-lumen tube, SpO2 = arterial oxygen saturation, TCI = targeted controlled infusion.

Keywords: anesthesia, complications, extubation trachea, pharmacology, remifentanil

1. Introduction

Coughing during emergence from anesthesia and tracheal extubation can be associated with various adverse events such as laryngospasm, hypertension, tachycardia, and increased intracranial and intraabdominal pressure.[1] Various methods have been tried to prevent coughing during emergence from anesthesia and tracheal extubation.[12–41] Opioids are used as a treatment for coughing and recent studies have reported an antitussive effect of remifentanil during recovery from general anesthesia by suppressed coughing.[5–7] The effective effect-site concentration (Ce) of remifentanil for 50% and 95% of patients (EC50 and EC95) that prevents cough during emergence after general anesthesia using single-lumen tube (SLT) has been determined.[7–10]

A double-lumen tube (DLT) is currently used to facilitate surgical exposure in patients undergoing intrathoracic surgical procedure. Use of the larger DLT increases the incidence of hoarseness and airway injury,[11] and can stimulate different parts of the respiratory tracts compared with SLT. Some reports described that the coughing reflex differs throughout the respiratory tract from the larynx to the bronchi.[12–17] But, to date, there is no report with regard to effective Ce of remifentanil for preventing cough during emergence using DLT. The proper dose of remifentanil needed to prevent coughing during DLT extubation.

The purpose of this study was to evaluate the EC50 and EC95 of remifentanil in effect-site concentration for preventing cough during emergence after general anesthesia using DLT.

2. Methods

The study was approved by the Institutional Review Board of Ajou University Hospital (Ref: AJIRB-MED-CT4-14-456). After
written informed consent was obtained from participants, 25 American Society of Anesthesiologists physical status (ASA) physical status 1 and 2 patients, aged 20 to 65 years who were undergoing video-assisted thoracoscopic lung surgery requiring 1-lung ventilation in Ajou medical center were enrolled. Exclusion criteria were administration of an angiotensin-converting enzyme inhibitor, anticipated difficult airway, gastroesophageal reflux, asthma, chronic obstructive disease, and upper respiratory infection. The trial is registered in a public trial register (Clinical Research Information Service, CRIS) under the identification number KCT0001563.

All patients were evaluated before surgery and were not premedicated. Patients were monitored with electrocardiography, arterial oxygen saturation (SpO2), noninvasive blood pressure, and bispectral index (BIS). For effect-site targeted-controlled infusion (TCI) of remifentanil, a commercial TCI pump (Orchestra Base Primea, Fresinus Vial, France) was used. The pumps were operated by the Minto pharmacokinetic model for remifentanil.14

All patients were preoxygenated with 100% oxygen for 1 minute and anesthesia was induced using intravenous propofol 1.5 mg/kg and effect-site TCI of remifentanil. Remifentanil infusion began at the time of anesthetic induction. After the patient did not respond to verbal command, rocuronium 0.6 mg/kg was given intravenously and manual ventilation with 100% oxygen was done for 90 seconds. After confirming a BIS value below 60, tracheal intubation was performed in all patients with a 3.5-Fr DLT. The correct positioning of DLT was confirmed with fiberoptic bronchoscopy. If repositioning was necessary, the DLT was guided into position via bronchoscope. Cuff pressure was set to 20 to 25 mm Hg with a hand pressure gauge. Anesthesia was maintained with sevoflurane and effect-site TCI of remifentanil at 2.5 to 4.0 ng/ml to maintain blood pressure and heart rate within 20% of baseline value, and to maintain a BIS target level of 40 to 60 during surgery. Lungs were ventilated with 50% oxygen during the initial 2-lung ventilation period and the fraction of oxygen was changed to 100% during the 1-lung ventilation period. End-tidal CO2 was maintained at 35 to 40 mm Hg during surgery. Lungs were ventilated with 50% oxygen during the initial 2-lung ventilation period and the fraction of oxygen was changed to 100% during the 1-lung ventilation period. End-tidal CO2 was maintained at 35 to 40 mm Hg during surgery. Patient’s core temperature was maintained at 36.5 ± 0.5°C. After completing the surgery, effect-site concentration of remifentanil was titrated to a predetermined concentration (initial concentration being 2.0 ng/ml for the first patient). Immediately after the surgical procedure, sevoflurane was stopped and sugammadex 4 mg/kg was given for reversal of neuromuscular block. Intravenous ibuprofen 400 mg was given for pain control. The predetermined concentration was maintained at least 10 minutes throughout emergence for the effect-site concentration and plasma concentration were anticipated to be stable. The patient was verbally requested to open their eyes without any stimulus. When the patient did so, deep breathing was encouraged; after adequate tidal volume and ventilatory frequency were confirmed, the DLT was removed with cuff deflated.

Cough, defined as a sudden contraction of the abdominal muscles, was assessed during anesthetic emergence from discontinuation to 2 minutes after extubation. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence. Similarly, if the patient coughed anytime during emergence, smooth emergence was considered to have failed and the predetermined concentration was increased by 0.5 ng/ml. The anesthesiologist who was blinded to the remifentanil effect-site concentration performed the extubation, and checked patients for coughing. After extubation, patient was given 100% oxygen via a face mask for 5 minutes before transfer to the postanesthesia care unit after confirming stable vital signs.

Bradyrhythmia, defined as a respiratory rate <8 rates per minute or a SpO2 <95% despite oxygen supplement and other respiratory complications were assessed during the emergence period. Mean arterial pressure and heart rate, SpO2, and BIS were recorded after completion of operation, immediately before and after extubation, and 2 minutes after extubation. Body temperature was recorded at the end of surgery. End-tidal CO2 and respiration rate were also recorded immediately after extubation. End-expiratory sevoflurane concentration at eye opening and the intervals from the discontinuation of sevoflurane to eye opening and to extubation were recorded.

For estimating EC50 and EC95 of remifentanil in preventing cough, the patients were enrolled until obtaining 6 crossover pairs according to the Dixon’s sequential allocation method.17 Twenty-five patients were included to obtain stable estimations. The EC50 of remifentanil was determined by calculating the average of the midpoint dose of all independent pairs of patients after 8 crossover points were obtained. The data were subjected to isotonic regression method for calculation of EC50 and EC95 with 95% confidence interval (CI).19 An adjusted response probability was calculated by the pooled adjacent-violators algorithm (PAVA), and the CI was estimated by a bootstrapping approach.20

All continuous variables, except for estimated EC, are shown as the mean ± SD or median (interquartile range) and comparison between cough suppression patients and failed cough suppression patients for duration of surgery and anesthesia, end-tidal sevoflurane concentration at eye opening and extubation, time to eye opening, and extubation were made with a Wilcoxon rank sum test. The numbers of ASA physical status were compared using Fisher exact test. Hemodynamic data during emergence between cough suppression patients and failed cough suppression patients were analysed by a Wilcoxon rank sum test. R statistical software package version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria) was used for statistical analysis. P < 0.05 was considered statistically significant.

3. Results

Using the Dixon up-and-down methods, 25 patients were enrolled. Among them, 2 patients were excluded due to surgical factors (main bronchus injury and postoperative ventilator therapy). Finally, 23 patients completed all the assessments. The patients’ characteristics are presented in Table 1.

The up-and-down results in consecutive patients and PAVA response rate are shown in Figs. 1 and 2. The EC50 of remifentanil

| Table 1 | Demographic data. |
|---------|-------------------|
| Age, y  | 51.0 (43–60)      |
| Weight, kg | 56.0 (52.9–60.3) |
| Height, cm | 158.0 (152.0–160.0) |
| ASA PS (Ⅲ) | 18 (78.3%)<sup>ⅳ</sup> (21.7%) |
| Operation | Lobectomy 17 Segmentectomy 4 Others 2 |
| Duration of surgery, min | 80.0 (55.0–102.5) |
| Duration of anesthesia, min | 150.0 (115.0–177.5) |

Values are presented as median (1st quartile–3rd quartile) or number of patients (%).
ASA PS = American Society of Anesthesiologists physical status.
needed to prevent cough during emergence, estimated by the Dixon
method, was 1.75 ng/mL ± 0.27. EC50 and EC95 of remifentanil as
estimated by the isotonic regression model with a bootstrapping
approach was 1.670 ng/mL (95% CI 1.393–1.806) and
2.275 ng/mL (95% CI 1.950–2.636), respectively.

The comparisons of recovery profiles and hemodynamic values
after anesthesia between the patients without cough (n = 12)
and those with cough (n = 11) are presented in Tables 2 and 3.
There were no differences in recovery profiles and hemodynamic
values after anesthesia between patients with cough and patients
without cough except height.

No patients suffered any respiratory complications during the
emergence period.

Figure 1. Assessment of success or failure to prevent cough during
emergence with predetermined concentrations of remifentanil from con-
secutive patients by the Dixon up-and-down method.

Figure 2. Pooled adjacent violators algorithm response rate. The EC50
of remifentanil was 1.670 ng/mL (95% CI 1.393–1.806). The EC95 of remifentanil
was 2.275 ng/mL (95% CI 1.950–2.636). CI, confidence interval; EC50, effective Ce of remifentanil for suppression of emergence cough in 50% of
patients; EC95, effective Ce of remifentanil for suppression of emergence cough in 95% of patients.

4. Discussion

The EC50 and EC95 of remifentanil via effect-site TCI to prevent
coughing emergence from sevoflurane anesthesia in female
patients requiring DLT intubation was 1.670 and 2.275 ng/mL,
respectively. No patient suffered from desaturation, hypoventilation,
and all were discharged from PACU without any adverse
events.

Several studies have demonstrated the usefulness of opioids for
preventing cough. The antitussive effect of opioids is primarily
central, and maintaining a certain effect site opioid concentration
with TCI is considered reliable.[17] Remifentanil is an ultrashort-
acting opioid that is a suitable agent for this purpose, because its
effect quickly and predictably disappears after cessation without
delayed recovery from anesthesia.[22,23] In several studies, a TCI
of remifentanil during anesthetic emergence was reported to
allow patients to recover from general anesthesia without
coughing or hemodynamic instability.[8,23,24] and several studies
extrapolated the effective Ce of remifentanil for preventing
airway reflexes during anesthetic emergence.[7–10]

Knowledge of the remifentanil concentration in a particular
patient undergoing a specific situation (procedure, use of
anesthetic agents) is necessary because various factors influence
the EC of remifentanil to suppress cough[9,10,25–27]; Sex affects the
analgiesic effects of opioids and the requirements of opioids
for preventing cough during extubation is higher in male than in
female.[25,26] The type of anesthetic agents used, such as propofol,
sevoflurane, and desflurane, change the incidence of coughing
during emergence.[9,27] Airway irritation, including that due to an
dotracheal tube, also could enhance the cough response.[10]

Determining the EC50 and EC95 of remifentanil for preventing
cough in patients undergoing thoracic surgery requiring DLT
intubation is important, because the distal tip of the DLT can
reach to the main bronchus, which can stimulate different parts of
the respiratory tracts compared with SLT. Cough is a defensive
reflex of the respiratory tract that can be elicited from the larynx,
trachea, carina, or bronchi. These sites are unavoidably
stimulated by anesthesiologists during routine practice.[28] The
site of stimulation is crucial for determining the patterns of
protective response because the protective reflex responses from
the respiratory tract are vary, depending on the site of
stimulation, with conflicting results.[12–17] In this respect,
determination of the EC of remifentanil for the prevention of
cough induced by a DLT during anesthetic emergence is required
to achieve predictable and smooth emergence, so the investiga-
tion of EC50 and EC95 of remifentanil for these kinds of patients
would be clinically significant.[3]

In the up-and-down sequential allocation design, there
are several methods for estimating EC: the Dixon method,
logistic/probit regression, and isotonic regression.[19] Among these
methods, we adapted the isotonic regression method for
estimating the EC of remifentanil. Because the Dixon method
is a simplified design focusing on EC50, extrapolation to higher
quartiles such the EC95 calculated in an up-and-down sequential
allocation design may impose great bias and cannot be a reliable
value.[20] The estimated EC95 of remifentanil to prevent cough
cannot be readily applied to clinical practice and should be
confirmed in a properly designed study for determining EC95, like
a biased coin design that can directly estimate EC at any
quartile.[10]

This study investigated the EC of remifentanil to prevent cough
emergence only from sevoflurane anesthesia. Anesthetic agents
variably affect the activities of the airway receptors. Volatile
Table 2

Comparison of recovery profiles during anesthetiic emergence between patients without cough and with cough.

|                                | Patients without cough (n=12) | Patients with cough (n=11) | P     |
|--------------------------------|-------------------------------|----------------------------|-------|
| Age, y                         | 54.5 (49.8–61.0)              | 47.0 (37.0–56.0)            | 0.16  |
| Weight, kg                     | 56.0 (53.4–60.9)              | 56.0 (53.4–60.0)            | 0.85  |
| Height, cm                     | 153.5 (150.4–158.0)           | 160.0 (157.5–161.5)         | 0.01  |
| ASA PS (I/II)                  | 11 (91.7%)/1 (8.3%)           | 7 (63.6%)/4 (36.4%)         | 0.16  |
| Duration of surgery, min       | 87.5 (78.8–106.2)             | 70 (47.5–97.5)              | 0.19  |
| Duration of anesthesia, min    | 160.0 (138.8–176.2)           | 120.0 (97.5–177.5)          | 0.30  |
| Et Sevo conc. at eye open (%)  | 0.25 (0.2–0.4)                | 0.3 (0.2–0.3)               | 0.72  |
| Time to eye opening, min       | 7.7 (6.1–8.7)                 | 8.3 (6.3–9.5)               | 0.61  |
| Time to extubation, min        | 8.4 (7.8–10.0)                | 8.7 (7.5–10.4)              | 0.85  |
| BIS score                      |                               |                            |       |
| At the end of surgery          | 56.5 (53.3–59.5)              | 50.0 (45.5–55.5)            | 0.14  |
| Before extubation              | 86.0 (73.8–90.0)              | 79.0 (77.0–83.0)            | 0.24  |
| Immediately after extubation   | 86.0 (85.0–90.0)              | 85.0 (80.5–85.5)            | 0.08  |
| 2 min after extubation         | 90.0 (88.6–90.5)              | 90.0 (80.0–92.5)            | 0.54  |
| Temperature at the end of surgery | 35.7 (35.2–36.2)          | 35.3 (34.6–36.6)            | 0.12  |
| EtCO2 (mm Hg) immediately after extubation | 36.5 (34.0–38.8)         | 35.0 (33.0–38.0)            | 0.50  |
| Respiratory rate immediately after extubation | 9.0 (8.0–10.0)          | 8.0 (8.0–9.0)               | 0.83  |

Values are presented as median (1st quartile–3rd quartile) or number of patients (%). ASA PS = American Society of Anesthesiologists physical status, BIS = bispectral index, Et = end-tidal concentration.

Table 3

Comparison of hemodynamic profiles during anesthetiic emergence between patients without cough and with cough.

|                                | Patients without cough (n=12) | Patients with cough (n=11) | P     |
|--------------------------------|-------------------------------|----------------------------|-------|
| MAP (mm Hg)                    |                               |                            |       |
| At the end of surgery          | 90.0 (80.8–100.0)             | 87.0 (83.5–101.5)          | 0.95  |
| Before extubation              | 101.0 (93.0–108.0)            | 110.0 (93.0–114.0)         | 0.64  |
| Immediately after extubation   | 102.0 (98.5–106.2)            | 104.0 (100.5–115.5)        | 0.42  |
| 2 min after extubation         | 102.58 (94.0–105.5)           | 102.0 (96.5–117.5)         | 0.64  |
| HR, bpm                        |                               |                            |       |
| At the end of surgery          | 71.0 (62.8–77.5)              | 61.0 (55.0–73.5)           | 0.34  |
| Before extubation              | 70.0 (62.0–81.3)              | 76.0 (60.0–78.5)           | 0.85  |
| Immediately after extubation   | 78.0 (68.8–83.0)              | 88.0 (73.5–92.0)           | 0.34  |
| 2 min after extubation         | 78.5 (72.8–85.5)              | 75.0 (65.0–84.5)           | 0.50  |

Values are presented as median (1st quartile–3rd quartile). HR = heart rate, MAP = mean arterial pressure.

Anesthetics stimulate the laryngeal receptors and inhibit the pulmonary irritant receptors. Several reports showed that propofol suppresses airway reflexes; propofol decreases the likelihood of laryngospasm and the probability of cough. Some studies suggested that emergence cough occurs less frequently and less severely after propofol-based total intravenous anesthesia compared with sevoflurane anesthesia. Therefore, knowledge of the EC of remifentanil for preventing cough during emergence for different anesthetic agents, especially propofol, is needed.

This study has several limitations. First, we did not measure real plasma concentrations of remifentanil from patient blood sampling. However, because the Minto pharmacokinetic model, used for remifentanil TCI, has been commonly used with acceptable bias and accuracy in clinical situation, this predicted EC of remifentanil can be used reliably in clinical practice. Second, the study population was limited to females between 20 and 65 years of age. Gender may affect opioid effect; males are less sensitive to the analgesic effects of opioid than females and older patients are more sensitive to opioids. These factors should be considered when interpreting the data.

In conclusion, remifentanil can be a safe and reliable means of cough prevention during emergence from sevoflurane anesthesia after thoracic surgery requiring DLT. The EC50 and EC95 of remifentanil that suppress coughing is 1.670 and 2.275 ng/mL, respectively.

References

1. Jun N, Lee J, Song J, et al. Optimal effect-site concentration of remifentanil for preventing cough during emergence from sevoflurane-remifentanil anaesthesia. Anaesth Intensive Care 2010;38:930–5.
2. Guler G, Akin A, Tosun Z, et al. Single-dose dexmedetomidine attenuates emergence cough during propofol-based total intravenous anesthesia: A double-blind, randomised, placebo-controlled trial. Acta Anaesthesiol Scand 2005;49:1088–91.
3. Park SH, Han SH, Do SH, et al. Prophylactic dexamethasone decreases the incidence of sore throat and hoarseness after tracheal extubation with a double-lumen endobronchial tube. Anesth Analg 2008;107:1814.
4. Sumathi P, Shenoy T, Ambareesha M, Krishna H. Controlled comparison between betamethasone gel and lidocaine jelly applied over tracheal tube to reduce postoperative sore throat, cough, and hoarseness of voice. Br J Anaesth 2008;100:213–8.
5. Tagaito Y, Isono S, Nishino T. Upper airway reflexes during extubation. Acta Anaesthesiol Scand 1995;39:739–44.
6. Mendel P, Friedman B, White PF. Alfentanil suppresses coughing and agitation during emergence from isoflurane anesthesia. J Clin Anesth 1995;7:114–8.
7. Lee B, Lee JR, Na S. Targeting smooth emergence: the effect site concentration of remifentanil for preventing cough during emergence from propofol-remifentanil anaesthesia for thyroid surgery. Br J Anaesth 2009;102:775–8.

Lee et al. Medicine (2016) 95:24 Medicine
[8] Choi EM, Park WK, Choi SH, et al. Smooth emergence in men undergoing nasal surgery: the effect site concentration of remifentanil for preventing cough after sevoflurane-balanced anaesthesia. Acta Anaesthesiol Scand 2012;56:498–503.

[9] Lee JH, Choi SH, Choi YS, et al. Does the type of anesthetic agent affect remifentanil effect-site concentration for preventing endotracheal tube-induced cough during anaesthetic emergence? Comparison of propofol, sevoflurane, and desflurane. J Clin Anesth 2014;26:466–74.

[10] Choi SH, Min KT, Lee JR, et al. Determination of EC95 of remifentanil for smooth emergence from propofol anesthesia in patients undergoing transphenoidal surgery. J Neurosurg Anesthesiol 2015;27:160.

[11] Knoll H, Ziegeler S, Schreiber JU, et al. Airway injuries after one-lung ventilation: a comparison between double-lumen tube and endobronchial blocker. Anesthesiology 2006;105:471.

[12] Nishino T, Kochi T, Ishii M. Differences in respiratory reflex responses from the larynx, trachea, and bronchi in anesthetized female subjects. Anesthesiology 1996;84:70–4.

[13] Nishino T. Physiological and pathophysiological implications of upper airway reflexes in humans. Jpn J Physiol 2000;50:3–14.

[14] Sant’Ambrogio G, Remmers JE, de Groot WJ, et al. Localization of rapidly adapting receptors in the trachea and main stem bronchus of the dog. Respir Physiol 1978;33:359–66.

[15] Sant’Ambrogio G. Afferent pathways for the cough reflex. Bull Eur Physiopathol Respir 1987;23 (Suppl 10):19–23.

[16] Tatar M, Sant’Ambrogio G, Sant’Ambrogio FB. Laryngeal and tracheobronchial cough in anesthetized dogs. J Appl Physiol 1994;76:2672–9.

[17] Psarras TE, Jonzon A, Coleridge HM, Coleridge JC. Vagal afferent and reflex responses to changes in surface osmolarity in lower airways of dogs. J Appl Physiol 1992;73:2305–13.

[18] Minto CF, Schneider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997;86:10–23.

[19] Stylianou M, Hourmov N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002;58:171.

[20] Pace NL, Stylianou MP. Advances in and limitations of up-and-down methodology: a review of clinical use, study design, and dose estimation in anaesthesia research. Anesthesiology 2007;107:144–52.

[21] Dilleen M, Heimann G, Hirsch I. Non-parametric estimators of a monotonic dose-response curve and bootstrap confidence intervals. Stat Med 2003;22:869–2.

[22] Glass PS, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth Analg 1993;77:1031–40.

[23] Nho JS, Lee SY, Kang JM, et al. Effects of maintaining a remifentanil infusion on the recovery profiles during emergence from anaesthesia and tracheal extubation. Br J Anaesth 2009;103:817–21.

[24] Lee JH, Koo BN, Jeong JJ, et al. Differential effects of lidocaine and remifentanil on response to the tracheal tube during emergence from general anaesthesia. Br J Anaesth 2011;106:410–5.

[25] Dahan A, Kest B, Waxman AR, Sarton E. Sex-specific responses to opiates: animal and human studies. Anesth Analg 2008;107:83–95.

[26] Soh S, Park WK, Kang SW, et al. Sex differences in remifentanil requirements for preventing cough during anaesthetic emergence. Yonsei Med J 2014;55:807–14.

[27] Hohlrieder M, Tiefenthaler W, Klaus H, et al. Effect of total intravenous anaesthesia and balanced anaesthesia on the frequency of coughing during emergence from the anaesthesia. Br J Anaesth 2007;99:587–91.

[28] Hamaya Y, Dohi S. Differences in cardiovascular response to airway stimulation at different sites and blockade of the responses by lidocaine. Anesthesiology 2000;93:95–103.

[29] Nishino T, Anderson JW, Sant’Ambrogio G. Effects of halothane, enfurane, and isoﬂurane on laryngeal receptors in dogs. Respir Physiol 1993;91:247–60.

[30] Nishino T, Anderson JW, Sant’Ambrogio G. Responses of tracheobronchial receptors to halothane, enfurane, and isoflurane in anesthetized dogs. Respir Physiol 1994;95:281–94.

[31] Hans P, Marechal H, Bonhomme V. Effect of propofol and sevoflurane on coughing in smokers and non-smokers awakening from general anaesthesia at the end of a cervical spine surgery. Br J Anaesth 2008;101:731.

[32] Barra YK, Ivanova M, Ali SS, et al. The efficacy of a subhypnotic dose of propofol in preventing laryngospasm following tonsillectomy and adenoidectomy in children. Paediatr Anaesth 2005;15:1094–7.

[33] McKeating K, Bali IM, Dundee JW. The effects of thiopentone and propofol on upper airway integrity. Anaesthesia 1988;43:638–40.

[34] Brown GW, Patel N, Ellis FR. Comparison of propofol and thiopentone for laryngeal mask insertion. Anaesthesia 1991;46:771–2.

[35] Mertens MJ, Engbers FH, Burm AG, Vuyk J. Predictive performance of computer-controlled infusion of remifentanil during propofol/remifentanil anaesthesia. Br J Anaesth 2003;90:132–41.